Você pesquisou por y - Critical Care Science (CCS)

You searched for:"Pablo Cardinal-Fernández"

We found (2) results for your search.
  • ORIGINAL ARTICLE

    Pretreatment with adalimumab reduces ventilator-induced lung injury in an experimental model

    Revista Brasileira de Terapia Intensiva. 05-08-2020;32(1):58-65

    Abstract

    ORIGINAL ARTICLE

    Pretreatment with adalimumab reduces ventilator-induced lung injury in an experimental model

    Revista Brasileira de Terapia Intensiva. 05-08-2020;32(1):58-65

    DOI 10.5935/0103-507X.20200010

    Views33

    ABSTRACT

    Objective:

    To determine whether adalimumab administration before mechanical ventilation reduces ventilator-induced lung injury (VILI).

    Methods:

    Eighteen rats randomized into 3 groups underwent mechanical ventilation for 3 hours with a fraction of inspired oxygen = 0.40% including a low tidal volume group (n = 6), where tidal volume = 8mL/kg and positive end-expiratory pressure = 5cmH2O; a high tidal volume group (n = 6), where tidal volume = 35mL/kg and positive end-expiratory pressure = 0; and a pretreated + high tidal volume group (n = 6) where adalimumab (100ug/kg) was administered intraperitoneally 24 hours before mechanical ventilation + tidal volume = 35mL/kg and positive end-expiratory pressure = 0. ANOVA was used to compare histological damage (ATS 2010 Lung Injury Scoring System), pulmonary edema, lung compliance, arterial partial pressure of oxygen, and mean arterial pressure among the groups.

    Results:

    After 3 hours of ventilation, the mean histological lung injury score was higher in the high tidal volume group than in the low tidal volume group (0.030 versus 0.0051, respectively, p = 0.003). The high tidal volume group showed diminished lung compliance at 3 hours (p = 0.04) and hypoxemia (p = 0,018 versus control). Pretreated HVt group had an improved histological score, mainly due to a significant reduction in leukocyte infiltration (p = 0.003).

    Conclusion:

    Histological examination after 3 hours of injurious ventilation revealed ventilator-induced lung injury in the absence of measurable changes in lung mechanics or oxygenation; administering adalimumab before mechanical ventilation reduced lung edema and histological damage.

    See more
    Pretreatment with adalimumab reduces ventilator-induced lung injury in an experimental model
  • Review Articles

    What every intensivist should know about acute respiratory distress syndrome and diffuse alveolar damage

    Revista Brasileira de Terapia Intensiva. 09-28-2017;29(3):354-363

    Abstract

    Review Articles

    What every intensivist should know about acute respiratory distress syndrome and diffuse alveolar damage

    Revista Brasileira de Terapia Intensiva. 09-28-2017;29(3):354-363

    DOI 10.5935/0103-507X.20170044

    Views34

    ABSTRACT

    Acute respiratory distress syndrome is a challenging entity for the intensivist. The pathological hallmark of the acute phase is diffuse alveolar damage, which is present in approximately half of living patients with acute respiratory distress syndrome. It is clear that respiratory support for acute respiratory distress syndrome has gradually been improving over recent decades. However, it is also evident that these procedures are beneficial, as they reduce lung injury and keep the patient alive. This could be interpreted as a time-gaining strategy until the trigger or causal or risk factor improves, the inflammatory storm decreases and the lung heals. However, all except two pharmacological treatments (neuromuscular blockers and steroids) were unable to improve the acute respiratory distress syndrome outcome. The hypothesis that pharmacological negative results may be explained by the histological heterogeneity of acute respiratory distress syndrome has been supported by the recent demonstration that acute respiratory distress syndrome with diffuse alveolar damage constitutes a specific clinical-pathological entity. Given that diffuse alveolar damage is a pathological diagnosis and that open lung biopsy (the most common technique to obtain lung tissue) has several side effects, it is necessary to develop surrogate biomarkers for diffuse alveolar damage. The aim of this narrative review is to address the following three topics related to acute respiratory distress syndrome: (a) the relationship between acute respiratory distress syndrome and diffuse alveolar damage, (b) how diffuse alveolar damage could be surrogated in the clinical setting and (c) how enrichment in diffuse alveolar damage may improve the results of pharmacological clinical trials tried out on patients with acute respiratory distress syndrome.

    See more
    What every intensivist should know about acute respiratory distress syndrome and diffuse alveolar damage

Search

Search in:

Article type
article-commentary
brief-report
case-report
correction
editorial
letter
other
rapid-communication
reply
research-article
review-article
Section
Article
Articles
Artigo de Revisão
Artigo de Revisão - Pediatria
Artigo de Revisão de Pediatria
Artigo Original
Artigo Original - Enfermagem
Artigo Original - Neonatologia
Artigo Original de Pediatria
Artigo Original Destaque
Artigos de Revisão
Artigos Originais
AUTHOR’S RESPONSE
AUTHORS’ RESPONSE
BRIEF COMMUNICATION
Carta ao Editor
CARTAS AO EDITOR
Case Report
Case Report
Case Reports
CLINICAL REPORT
Comentário
Comentários
COMMENTARIES
COMMENTARY
Consenso Brasileiro de Monitorização e Suporte Hemodinâmico
Correspondence
Editorial
EDITORIALS
Erratum
Erratum
Guidelines and Consensus
III Consenso Brasileiro de Ventilação Mecância
Informação Clínica
LETTER TO THE EDITOR
Letter to the Editor
Letters to the Editor
NARRATIVE REVIEW
ORIGINAL ARTICLE
ORIGINAL ARTICLE
Original Article - Basic Research
Original Article - Neonatologia
Original Article - Pediatria
Original Articles
Original Articles - Basic Research
Original Articles - Clinical Research
Relato de Caso
Relatos de Caso
Relatos de Casos
Research Letter
REVIEW
Review Article
Review Articles
Série: Medicina baseada em evidências e terapia intensiva
Série: Terminalidade em UTI
SPECIAL ARTICLE
Special Article
Special Articles
Terminalidade em UTI pediátrica
Viewpoint
Year / Volume
2025; v.37
2024; v.36
2023; v.35
2022; v.34
2021; v.33
2020; v.32
2019; v.31
2018; v.30
2017; v.29
2016; v.28
2015; v.27
2014; v.26
2013; v.25
2012; v.24
2011; v.23
2010; v.22
2009; v.21
2008; v.20
2007; v.19
2006; v.18
ISSUE